Galecto: Funding, Investors & Team (Sep 2026)
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto has raised $275M across 1 funding round on record, the most recent an undisclosed round of $275M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Galecto Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Galecto Funding Rounds
Galecto Founders and Leadership Team
No contact details are on record for this team yet.
Galecto Funding Compared to Other Biotechnology Startups
Galecto's latest round of $275M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Galecto in Biotechnology and Copenhagen
Companies Similar to Galecto
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several…
Alcolase is a Danish life science start-up that specializes in alcohol flushing.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on…
ENZIDIA is unleashing the biomanufacturing revolution with an enzyme acceleration revolution
Gefjon Pharma is a biopharmaceutical company focused on developing innovative solutions to combat…
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly…
Pioneering new sustainable bio-based ingredients
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or…
EvodiaBio is a company in the bio-industrial sector that develops eco-friendly fragrances for the food and…
Fida Biosystems is a technology that provides the detection and characterization of proteins and…
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived…
WiLD is a networking platform for women in senior positions in business and academia that is motivating and…
Galecto Funding FAQs
What does Galecto do?
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
How much funding has Galecto raised?
Galecto has raised $275M across 1 round on record. The most recent is an undisclosed round of $275M announced in Feb 2026.
When did Galecto last raise funding?
Galecto's most recent funding round on record is an undisclosed round of $275M, announced in Feb 2026.
Who founded Galecto?
FundedIQ lists Tariq Sethi (Founder) at Galecto.
Where is Galecto headquartered?
Galecto is based in Copenhagen, Hovedstaden, Denmark.
How many employees does Galecto have?
Galecto is in the 11-50 employee band.
How does Galecto's funding compare to other Biotechnology startups?
Galecto's latest round of $275M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Galecto Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Galecto is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.